MindWalk Holdings (HYFT) EBITDA Margin (2020 - 2026)
MindWalk Holdings (HYFT) reported EBITDA Margin of 0.51% for Q1 2026, down 77213.0% year-over-year from N/an in Q1 2025, and down 100.0% quarter-over-quarter from 75751697.38% in Q4 2025.
MindWalk Holdings (HYFT) EBITDA Margin (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 7 years of EBITDA Margin data on file, last reported at 0.51% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 0.51%, down 77213.0% year-over-year; the trailing twelve-month figure through Jan 2026 was 39562.25% (down 6895457.0% YoY), and the FY2025 annual result was 118658.24%, down 11852552.0% from the prior year.
- EBITDA Margin declined to 0.51% in Q1 2026 per HYFT's latest filing, from 75751697.38% in the prior quarter.
- Over five years, EBITDA Margin peaked at 140719773554387.38% in Q3 2024 and troughed at 24265864.49% in Q2 2025.
- A 5-year average of 8277641505040.23% and a median of 18.39% in 2023 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2024 and 2025: EBITDA Margin soared 2000000000 bps in 2024, then plunged 2000000000 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 103.24% in 2022, then tumbled by 67 bps to 34.24% in 2023, then soared by 160 bps to 88.95% in 2024, then surged by 85160956 bps to 75751697.38% in 2025, then tumbled by 100 bps to 0.51% in 2026.
- Business Quant data shows HYFT's EBITDA Margin at 0.51% in Q1 2026, 75751697.38% in Q4 2025, and 110.09% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | -0.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -0.51% |
| Oct 31, 2025 | 75,751,697.38% |
| Jul 31, 2025 | -110.09% |
| Apr 30, 2025 | -24,265,864.49% |
| Jan 31, 2025 | 771.63% |
| Oct 31, 2024 | 88.95% |
| Jul 31, 2024 | 140,719,773,554,387.38% |
| Apr 30, 2024 | -345.72% |
| Jan 31, 2024 | 49.53% |
| Oct 31, 2023 | 34.24% |
| Jul 31, 2023 | 80,625,879.04% |
| Apr 30, 2023 | -153.82% |
| Jan 31, 2023 | 18.39% |
| Oct 31, 2022 | 103.24% |
| Jul 31, 2022 | -0.24% |
| Apr 30, 2022 | -81.83% |
| Jan 31, 2022 | -80,789.20% |
| Oct 31, 2021 | -118.38% |
| Jul 31, 2021 | -72.89% |
| Apr 30, 2021 | -63.54% |